The race to develop new immunotherapy treatments against cancer has sparked an unprecedented expansion in the oncology drug pipeline, with more than 2,000 immune system boosting agents now in development. The result is a scramble for patients to enroll in clinical trials; this year alone, 469 new clinical studies were started, with a target enrollment of 52,539 patients. (Newsmax Health)